C2 $R_4$ is selected from the group consisting of methyl, ethyl, oxo, isopropyl, n-propyl, isobutyl, n-butyl, t-butyl, 2-hydroxyethyl, 3-hydroxypropyl, 3-hydroxy-n-butyl, 2methoxyethyl, 4-methoxy-n-butyl, 5-hydroxyhexyl, 2-bromopropyl, 3-dimethylaminobutyl, 4-chloropentyl, methylamino, methylaminomethyl, dimethylamino, aminomethyl, and methylphenyl.

22. (Amended) The compound of claim 1, wherein $R_1$ is 5-hydroxyhexyl, $R_2$ is methyl and $R_3$ is hydrogen.

C3 23. (Amended) The compound of claim 1, wherein $R_1$ is 5-hydroxyhexyl, and $R_2$ and $R_3$ are methyl.

24. (Amended) The compound of claim 1, wherein $R_1$ is 5-hydroxyhexyl, $R_2$ is methyl and $R_3$ is $-CH_2OEt$.

25. (Amended) The compound of claim 1, wherein $R_1$ is 5-hydroxyhexyl, $R_3$ is methyl and $R_4$ is hydrogen.

**REMARKS**

This supplemental amendment is submitted to claims 1, 3 and 22-25. No new matter has been added. Specifically, claim 1 has been amended to include a dialkylamino moiety in $R_4$. Support for this amendment can be found at, *inter alia*, page 25 and in Table 2, page 110, Ex. R, Compound No. CT12485. The claim has also been further amended to correct an obvious error with respect to the term "$C_{(1-20)}$tetraaminoalkyl." Since there must be a bond open to bond the group to Z in the formula set forth in the claim, a group having one carbon (a methyl group) is chemically impossible. Accordingly, the term has been changed to --$C_{(2-20)}$tetraaminoalkyl--.

Claim 3 has been amended to add two moieties for $R_4$, namely, methylaminomethyl and dimethylamino. Support for these moieties can be found at, *inter alia*, page 25 of the


specification and in Table 2 on pages 109-110 of the specification, namely, Examples H and R, respectively.

Claims 22-25 have been amended to correct an obvious error. The claims should have recited $R_1$ as 5-hydroxylhexyl. These claims were presented to cover the compounds in Table 1 on pages 27-76 of the specification. Support for the claims can be found in Table 1 and in original claim 9.

Favorable consideration and prompt allowance of the pending claims are respectfully requested. To the extent necessary, a petition for an extension of time under 37 C.F.R. 1.136 is hereby made. Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

MCDERMOTT, WILL & EMERY



Cameron K. Weiffenbach
Registration No. 44,488

Willem F. Gadiano
Registration No. 37,136


600 13th Street, N.W.
Washington, DC 20005-3096
(202) 756-8000 CKW:MWE
Facsimile: (202) 756-8087
**Date: January 6, 2003**

## APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

*Please amend claims 1, 3 and 22-25 as follows:*

1. (Four Times Amended) A therapeutic compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula (I):




I

wherein:

X and Y are N or N($R_3$);

Z is C($R_4$);

$R_1$ is selected from a member of the group consisting of hydrogen, methyl, $C_{(5-9)}$alkyl, $C_{(5-9)}$alkenyl, $C_{(5-9)}$alkynyl, $C_{(5-9)}$hydroxyalkyl, $C_{(3-8)}$alkoxyl, $C_{(5-9)}$alkoxyalkyl, the $R_1$ being optionally substituted;

$R_2$[,] and $R_3$ [and $R_4$] are independently selected from a member of the group consisting of hydrogen, halo, oxo, $C_{(1-20)}$alkyl, $C_{(1-20)}$hydroxyalkyl, $C_{(1-20)}$thioalkyl, $C_{(1-20)}$alkylamino, $C_{(1-20)}$alkylaminoalkyl, $C_{(1-20)}$aminoalkyl, $C_{(1-20)}$aminoalkoxyalkenyl, $C_{(1-20)}$aminoalkoxyalkynyl, $C_{(1-20)}$diaminoalkyl, $C_{(1-20)}$triaminoalkyl, [$C_{(1-20)}$tetraaminoalkyl] $C_{(2-20)}$tetraaminoalkyl, $C_{(5-15)}$aminotrialkoxyamino, $C_{(1-20)}$alkylamido, $C_{(1-20)}$alkylamidoalkyl, $C_{(1-20)}$amidoalkyl, $C_{(1-20)}$acetamidoalkyl, $C_{(1-20)}$alkenyl, $C_{(1-20)}$alkynyl, $C_{(3-8)}$alkoxyl, $C_{(1-11)}$alkoxyalkyl, and $C_{(1-20)}$dialkoxyalkyl;

$R_4$ is selected from a member of the group consisting of hydrogen, halo, oxo, $C_{(1-20)}$alkyl, $C_{(1-20)}$hydroxyalkyl, $C_{(1-20)}$thioalkyl, $C_{(1-20)}$alkylamino, dialkylamino, $C_{(1-20)}$alkylaminoalkyl,

$C_{(1-20)}$aminoalkyl, $C_{(1-20)}$aminoalkoxyalkenyl, $C_{(1-20)}$aminoalkoxyalkynyl, $C_{(1-20)}$diaminoalkyl, $C_{(1-20)}$triaminoalkyl, $C_{(2-20)}$tetraaminoalkyl, $C_{(5-15)}$aminotrialkoxyamino, $C_{(1-20)}$alkylamido, $C_{(1-20)}$alkylamidoalkyl, $C_{(1-20)}$amidoalkyl, $C_{(1-20)}$acetamidoalkyl, $C_{(1-20)}$alkenyl, $C_{(1-20)}$alkynyl, $C_{(3-8)}$alkoxyl, $C_{(1-11)}$alkoxyalkyl, and $C_{(1-20)}$dialkoxyalkyl; and

— - — - represents a double or single bond;

with the proviso that $R_1$ is not an ω-1-hydroxyalkyl group having from 5 to 9 carbon atoms when $R_3$ is hydrogen or methyl and $R_4$ is hydrogen.

3. (Twice Amended) The therapeutic compound of claim 1, wherein

$R_3$ [and $R_4$ are] is selected from the group consisting of methyl, ethyl, oxo, isopropyl, n-propyl, isobutyl, n-butyl, t-butyl, 2-hydroxyethyl, 3-hydroxypropyl, 3-hydroxy-n-butyl, 2methoxyethyl, 4-methoxy-n-butyl, 5-hydroxyhexyl, 2-bromopropyl, 3-dimethylaminobutyl, 4-chloropentyl, methylamino, aminomethyl, and methylphenyl; and

$R_4$ is selected from the group consisting of methyl, ethyl, oxo, isopropyl, n-propyl, isobutyl, n-butyl, t-butyl, 2-hydroxyethyl, 3-hydroxypropyl, 3-hydroxy-n-butyl, 2methoxyethyl, 4-methoxy-n-butyl, 5-hydroxyhexyl, 2-bromopropyl, 3-dimethylaminobutyl, 4-chloropentyl, methylamino, methylaminomethyl, dimethylamino, aminomethyl, and methylphenyl.

22. (Amended) The compound of claim 1, wherein $R_1$ is [2-hydroxyhexyl] 5-hydroxyhexyl, $R_2$ is methyl and $R_3$ is hydrogen.

23. (Amended) The compound of claim 1, wherein $R_1$ is [2-hydroxyhexyl] 5-hydroxyhexyl, and $R_2$ and $R_3$ are methyl.

24. (Amended) The compound of claim 1, wherein $R_1$ is [2-hydroxyhexyl] 5-hydroxyhexyl, $R_2$ is methyl and $R_3$ is $-CH_2OEt$.

25. (Amended) The compound of claim 1, wherein $R_1$ is [2-hydroxyhexyl] 5-hydroxyhexyl, $R_3$ is methyl and $R_4$ is hydrogen.